Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.46 |
| ▸ | GAA | P10253 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13203896 | 0.81 | GFER (0.46) | MAPTGAAKMT2AMEN1HTT | |
| SCHEMBL10113801 | 0.76 | GFER (0.46) | MAPTGAAKMT2AMEN1HTT | |
| SCHEMBL8978487 | 0.76 | MEN1 (0.60) | MAPTGAAKMT2AMEN1HTT | |
| SCHEMBL9819666 | 0.75 | KMT2A (0.63) | MAPTGAAKMT2AMEN1HTT | |
| SCHEMBL13972703 | 0.74 | ALDH1A1 (0.57) | GAAKMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL8394269 | 0.74 | GAA (0.53) | MAPTGAAKMT2AMEN1HTT | |
| SCHEMBL12513507 | 0.73 | KMT2A (0.65) | MAPTGAAKMT2AMEN1HTT | |
| SCHEMBL9180518 | 0.73 | KMT2A (0.72) | MAPTGAAKMT2AMEN1HTT | |
| SCHEMBL8978503 | 0.72 | MTNR1A (0.68) | MAPTGAAKMT2AMEN1HTT | |
| SCHEMBL13052671 | 0.70 | GFER (0.60) | MAPTGAAKMT2AMEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8115027-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2012-02-14 | — | — | US | disclosed |
| US-20100292500-A1 | NPY Y5 ANTAGONIST | KAWANISHI YASUYUKI | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292500-A1 | NPY Y5 ANTAGONIST | NPY5R, NPY1R, NPY2R | MAPT 3367/4885GAA 3316/4885KMT2A 2768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.